Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th
August 09 2017 - 8:00AM
Business Wire
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical
company developing treatments for life-threatening food allergies,
today announced that CFO Eric Bjerkholt will present a company
overview at the 2017 Wedbush PacGrow Healthcare Conference in New
York on Wednesday, August 16, at 9:45 a.m. Eastern Time.
The live webcast of the presentation will be accessible on the
Events page under the Investor Relations section of the Aimmune
website at www.aimmune.com. The replay of the webcast will be
available for at least 30 days following the webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage
biopharmaceutical company developing treatments for
life-threatening food allergies. The company’s Characterized Oral
Desensitization ImmunoTherapy (CODIT™) approach is intended to
achieve meaningful levels of protection by desensitizing patients
with defined, precise amounts of key allergens. Aimmune’s first
investigational product using CODIT™, AR101 for the treatment of
peanut allergy, has received the FDA’s Breakthrough Therapy
Designation for the desensitization of peanut-allergic patients
4-17 years of age and is currently being evaluated in Phase 3
clinical trials in ages 4-55. AR101 is a characterized, regulated,
oral biological drug product containing the protein profile found
in peanuts. For more information, please see www.aimmune.com.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by
the U.S. Food and Drug Administration (FDA) or the European
Medicines Agency (EMA). It is currently limited to investigational
use, and no representation is made as to its safety or
effectiveness for the purposes for which it is being
investigated.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170809005230/en/
Aimmune Therapeutics, Inc.InvestorsLaura Hansen, Ph.D.,
650-396-3814lhansen@aimmune.comorMediaStephanie Yao,
650-351-6479syao@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Apr 2023 to Apr 2024